Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365803 | 0.84 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL77925 | 0.83 | ALDH1A1 (0.64) | ALDH1A1TDP1CYP3A4ALOX15CES2 | |
| SCHEMBL25837924 | 0.83 | ALDH1A1 (0.64) | ALDH1A1TDP1CYP3A4ALOX15CES2 | |
| SCHEMBL3242147 | 0.83 | ALDH1A1 (0.39) | ALDH1A1TDP1CYP3A4ALOX15CES2 | |
| Hydrochloric Acid SCHEMBL17164230 | 0.82 | ALDH1A1 (0.62) | ALDH1A1TDP1CYP3A4ALOX15CES2 | |
| SCHEMBL3240065 | 0.78 | ALDH1A1 (0.38) | ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL28281577 | 0.78 | ALDH1A1 (0.57) | ALDH1A1TDP1CYP3A4ALOX15CES2 | |
| SCHEMBL27604207 | 0.77 | CES2 (0.56) | ALDH1A1TDP1CYP3A4ALOX15CES2 | |
| Hydrazine SCHEMBL27447895 | 0.74 | CES2 (0.54) | ALDH1A1TDP1CYP3A4ALOX15CES2 | |
| SCHEMBL28612092 | 0.74 | ALDH1A1 (0.54) | ALDH1A1TDP1CYP3A4ALOX15CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418176-B1 | Pyrazole derivates, their preparation and their use in drugs | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-7300950-B2 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
| US-20050176799-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2005-08-11 | — | — | US | disclosed |
| US-6897232-B2 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-05-24 | — | — | US | disclosed |
| EP-1418176-A1 | Pyrazole derivates, their preparation and their use in drugs | Aventis Pharma Deutschland GmbH (DE) | 2004-05-12 | — | — | EP | disclosed |
| EP-0908456-B1 | Pyrazole derivatives, their preparation and their use in drugs | AVENTIS PHARMA GMBH (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030105336-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-06-05 | — | — | US | disclosed |
| US-6162819-A | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-19 | — | — | US | disclosed |
| CN-1214339-A | Pyrazole derivatives, their preparation and their use in pharmaceuticals | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-04-21 | — | — | CN | disclosed |
| EP-0908456-A1 | Pyrazole derivatives, their preparation and their use in drugs | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176799-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | PDE3A, PDE3B, PDE5A | ALDH1A1 977/4885TDP1 322/4885CYP3A4 212/4885 |
| US-20030105336-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | PDE3B, PDE3A, PDE5A | ALDH1A1 750/4885TDP1 299/4885CYP3A4 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.